CliffBio
biologic

Aranesp

darbepoetin alpha

Loss of exclusivitySeptember 2013projected — 12-year biologic exclusivity estimate
CompanyAmgen →See this company's full patent-cliff portfolio

Drug detail

Brand nameAranesp
Active ingredientdarbepoetin alpha
Strength25MCG/1ML
Dosage formInjection
RouteIntravenous, Subcutaneous
ModalityBiologic
FDA approvalSeptember 2001
Marketing statusRx

More from Amgen

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Aranesp patent cliff — loss of exclusivity September 2013 | CliffBio